Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$1.65
-13.6%
$1.95
$1.33
$3.58
$77.73M0.7463,856 shs106,937 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$2.00
-0.5%
$2.30
$0.98
$3.44
$80.64M0.2636,026 shs53,850 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.77
-1.3%
$3.48
$2.57
$6.88
$23.30M0.648,121 shs3,411 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.93
+2.4%
$2.46
$1.90
$3.79
$89.89M0.4216,094 shs283,122 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-16.59%+0.32%0.00%+10.06%-18.03%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-1.95%-1.95%-12.99%+19.32%+7.49%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+2.71%+3.86%+8.74%+17.49%-28.40%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
+0.70%-2.05%+20.17%+26.55%-15.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
2.8024 of 5 stars
3.55.00.00.02.01.70.0
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.1282 of 5 stars
0.03.00.00.03.31.70.6
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.3329 of 5 stars
0.05.00.00.01.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
3.00
Buy$7.50354.55% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NAII, ADAG, VTGN, and BYSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$100K777.32N/AN/A$1.14 per share1.45
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/A($0.37) per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.20N/AN/A$13.32 per share0.28
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$646K139.15N/AN/A$1.85 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$33.42MN/A0.00N/AN/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/A8/14/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.78N/AN/AN/A-6,777.08%-74.06%-64.10%N/A

Latest NAII, ADAG, VTGN, and BYSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.04N/A-$0.04N/AN/A
8/7/2025Q1 2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.47-$0.47N/A-$0.47$0.22 million$0.24 million
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.01
2.30
2.30
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.49
2.49
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
5.98
6.51

Institutional Ownership

CompanyInstitutional Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9.51%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
21.20%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
2.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
26047.11 million37.12 millionNot Optionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.32 million28.50 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4030.68 million29.81 millionOptionable

Recent News About These Companies

Vistagen (VTGN) Q1 R&D Expense Jumps 54%
VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adagene stock logo

Adagene NASDAQ:ADAG

$1.65 -0.26 (-13.61%)
Closing price 03:59 PM Eastern
Extended Trading
$1.85 +0.20 (+12.12%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$2.00 -0.01 (-0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 +0.00 (+0.25%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.80 -0.02 (-0.52%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.93 +0.07 (+2.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.95 +0.02 (+0.68%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.